Previous 10 | Next 10 |
2023-06-06 14:48:00 ET Wall Street has been on the upswing lately, gaining confidence about the ability of the economy to withstand inflationary pressures and tighter monetary policy. Small-cap stocks soared on Tuesday at midday, which helped drive the Nasdaq Composite (NASDAQINDEX: ^...
2023-06-06 13:11:07 ET Gainers: Recruiter.com Group ( RCRT ) +135% . Hoth Therapeutics ( HOTH ) +79% . Beamr Imaging ( BMR ) +32% . GitLab ( GTLB ) +31% . D-Wave Quantum ( QBTS ) +27% . MicroVision ( MVIS ) +23% . ...
2023-06-06 12:21:12 ET Major market indices fell during Tuesday's intraday session as investors began to assess the likelihood of another Federal Reserve interest rate hike. Gitlab ( NASDAQ: GTLB ) rose on solid Q1 earnings and an upbeat outlook, while Cracker Barrel Old Country...
2023-06-06 11:50:17 ET Shares of NovoCure (NASDAQ: NVCR) were crashing 29.6% lower as of 10:19 a.m. ET on Tuesday. The steep decline came after the company announced data for its Tumor Treating Fields (TTFields) therapy in treating non-small cell lung cancer (NSCLC) that it's presen...
2023-06-06 10:05:06 ET Gainers: Hoth Therapeutics ( HOTH ) +114% . Zura Bio ( ZURA ) +15% . TScan Therapeutics ( TCRX ) +12% . HealthEquity ( HQY ) +11% . ThermoGenesis ( THMO ) +7% . Losers: HTG Molecular Diagnostics ( ...
2023-06-06 09:02:06 ET NovoCure ( NASDAQ: NVCR ) lost ~10% while Zai Lab Limited ( ZLAB ) shed ~1% in the premarket Tuesday after the companies shared late-stage data for their cancer treatment device, Tumor Treating Fields (TTFields), in patients with lung cancer. A...
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpo...
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoin...
Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer ® , the ASCO Foundation, to advance cancer research and education. Conquer Cancer is a global community of advocates, patients, doctors, researchers, caregivers, and others dedicated to improving...
2023-05-27 06:14:00 ET You don't need much money to get started investing. And stocks with relatively low share prices have tremendous growth prospects. Three Fool.com contributors identified no-brainer healthcare stocks to buy for under $100. Here's why they chose CRISPR Therapeu...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...